| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 79 | 3.0x | 17.3x | Top tier | |
Growth | 81 | 3.3% | 7.1% | Top tier | |
Quality | 100 | 106.3% | 4.5% | Top tier | |
Safety | 86 | — | 2.6x | Top tier | |
Capital Return | 51 | 0.00% | 0.06% | Around median | |
Momentum | 94 | 70.4% | -1.6% | Top tier | |
Sentiment | 64 | 3 | 3 | Around median |
The floor: what the company is worth if growth stopped today
17% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 5.00% as of 2026-10-23. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Rigel Pharmaceuticals is a commercial-stage biopharmaceutical company focused on oncology and hematologic disorders, generating revenue from product sales in the United States and from collaboration, supply, and royalty revenue in international markets. Its commercial portfolio in Q2 fiscal 2026 included TAVALISSE, GAVRETO, and REZLIDHIA, and it subsequently added VEPPANU, or vepdegestrant, through an exclusive global license. The product is approved by the Food and Drug Administration for the treatment of advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation after at least one prior line of therapy. Net product sales were $67 million, while collaboration revenue was $11.7 million, indicating that direct commercial activity accounted for approximately 85% of total quarterly revenue.
In Q2 fiscal 2026, Rigel reported total revenue of $78.7 million and gross profit of $70.2 million, equivalent to a gross margin of approximately 89.2%, along with net income of $17.3 million and earnings per share of $0.88. Net product sales increased 14% year over year; TAVALISSE reached a record $47.4 million, up 18%, and REZLIDHIA generated approximately $8.9 million, up 27%, while GAVRETO sales were approximately $10.7 million, with a slight year-over-year decline. TAVALISSE alone accounted for approximately 71% of net product sales, while collaboration revenue included $5.8 million from Kissei, $5 million from Grifols, and $0.3 million from Medison.
Costs and expenses totaled $55.1 million in Q2 fiscal 2026, compared with $40.6 million in the corresponding fiscal 2025 period, due to higher research and development, product costs, and employee-related expenses. Income before taxes was $23.6 million, but net income declined from $59.6 million to $17.3 million because the corresponding period included $40 million in non-cash revenue related to the Lilly agreement. The company ended the quarter with $95.3 million in cash and short-term investments, down from $155 million at the end of fiscal 2025 after paying $70 million upfront for the VEPPANU license.
The average analyst price target is $67, within a wide range of $49 to $85, with a consensus Buy rating; the average is above the 52-week range high of $52.24, while the range low was $24.95. No displayed price-to-earnings multiple is available that can be relied upon despite the company generating net income, so the valuation depends heavily on the success of the VEPPANU launch and the sustainability of growth in current products; the approximately $36 spread in price targets also reflects meaningful variation in estimates of the portfolio's commercial value.
Figures in the text are as of 2026-09-18; the live price is shown at the top of the page.
Q2 fiscal 2026 revenue was approximately $78.7 million, including $67 million from product sales and $11.7 million from collaborations. TAVALISSE grew 18% to a record $47.4 million, and REZLIDHIA grew 27% to $8.9 million, while GAVRETO generated approximately $10.7 million. The company raised its fiscal 2026 revenue guidance to $285–295 million, excluding any contribution from VEPPANU from this range.
VEPPANU is the first PROTAC approved by the Food and Drug Administration for the treatment of advanced or metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation after at least one prior line of therapy. Management estimated that approximately 20 thousand patients are diagnosed and treated annually within this category in the United States, representing a market opportunity of more than $1 billion. In VERITAC-2, vepdegestrant increased median progression-free survival to 5.0 months from 2.1 months with fulvestrant, with an objective response rate of 18.6% versus 4%.
Automated analysis for informational purposes only — not investment advice.
R289 is an oral dual inhibitor of IRAK1 and IRAK4 being developed by Rigel for transfusion-dependent patients with lower-risk myelodysplastic syndrome after prior treatments. In dose-escalation data presented during the 2025 ASH meeting, 6 of 18 evaluable patients achieved red blood cell transfusion independence for at least eight weeks, which lasted more than 16 weeks in four patients and more than six months in three patients. The phase 1-B expansion is testing 500 milligram doses administered once and twice daily in up to 40 patients, with the company planning to release preliminary data by the end of fiscal 2026.
The rate of grade 3 or higher treatment-emergent adverse events was 23% with vepdegestrant versus 18% with fulvestrant. Fatigue was the most common adverse event at 27%, and elevated ALT and AST occurred in approximately 14%, while nausea occurred in 13% and diarrhea in 6%. Although QT prolongation is included among the warnings, no resulting clinical effects were recorded, and treatment discontinuations due to adverse events were 3%, with dose reductions at 2%.
TAVALISSE generated net sales of $47.4 million, accounting for approximately 71% of total product sales of $67 million. GAVRETO generated approximately $10.7 million, with a slight year-over-year decline, while REZLIDHIA generated approximately $8.9 million, up 27%. Partner agreements also contributed $11.7 million in collaboration revenue, including $5.8 million from Kissei and $5 million from Grifols.